Olaf Ortmann

Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

R. Charles Coombes, CF Snowdon, Robert Paridaens et al. · The Lancet · 2007 · 909 citations

Medicine, Endocrinology, Oncology +4

Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry

EC Inwald, Monika Klinkhammer‐Schalke, Ferdinand Hofstädter et al. · Breast Cancer Research and Treatment · 2013 · 608 citations · Full text

Medicine, Oncology, Pathology +16

Effect of Luteinizing Hormone–Releasing Hormone Agonist on Ovarian Function After Modern Adjuvant Breast Cancer Chemotherapy: The GBG 37 ZORO Study

Bernd Gerber, Gϋnter von Minckwitz, H. Stehle et al. · Journal of Clinical Oncology · 2011 · 296 citations

Medicine, Oncology, Pharmacotherapy +16

High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines.

Günter Emons, Olaf Ortmann, M. Becker et al. · PubMed · 1993 · 195 citations

Medicine, Oncology, Pharmacology +14

High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines.

Günter Emons, Bernd Schröder, Olaf Ortmann et al. · The Journal of Clinical Endocrinology & Metabolism · 1993 · 193 citations

Medicine, Endocrinology, Pharmacology +16